Digitoxin medication and cancer; case control and internal dose-response studies

BMC Cancer

Volumn 1, Issue , 2001, Pages

  Haux, Johan ^a   Klepp, Olbjøorn ^a   Spigset, Olav ^a   Tretli, Steinar ^b,c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIGITOXIN; ANTIARRHYTHMIC AGENT;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOMATION; CALCULATION; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HEART DISEASE; HUMAN; INFORMATION PROCESSING; KIDNEY CANCER; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; URINARY TRACT CANCER; AGE; BLOOD; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; INCIDENCE; NEOPLASM;

AGE FACTORS; AGED; ANTI-ARRHYTHMIA AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DIGITOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; MALE; NEOPLASMS;

EID: 3042611499     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-1-11     Document Type: Article

References (26)

1. Westheim A, Dickstein K, Gundersen T, Hole T, Kjekshus J, Myhre ES, Ronnevik PK, Samstad S, Smith P: [Chronic heart failure - suggestion to a management program]. Tidsskr Nor Laegeforen 1999, 119:3427-3431
2. Roever C, Ferrante J, Gonzalez EC, Pal N, Roetzheim RG: Comparing the toxicity of digoxin and digitoxin in a geriatric population: should an old drug be rediscovered? South Med J 2000, 93:199-202
3. Shiratori O: Growth inhibitory effect of cardiac glycosides and agly cones on neoplastic cells: in vitro and in vivo studies. Gann 1967, 58:521-528
4. Repke KRH: The role of the Na+/K+ pump in normal and cancer cell proliferation. In: Biomemebranes, Basic and Medical Research (Edited by Benga G, Tager JM) Berlin, Springer Verlag 1988161-176
5. Repke KR, Schon R, Megges R, Wetland J, Nissen E, Matthes E: Potential suitability of Na+/K(+)-transporting ATPase in prescreens for anti-cancer agents. Anticancer Drug Des 1995, 10:177-87
6. Cassady JM, Suffness M M: Terpenoid antitumor targets. In: Anti cancer agents based on natural product models (Edited by Cassady JM, Douros JD) New York, Academic Press 1980201-269
7. Haux J: Digitoxin is a potential anticancer agent for several types of cancer. Med Hypotheses 1999, 53:543-548
8. Haux J, Lam M, Marthinsen ABL, Strickert T, Lundgren S: Digitoxin, in non toxic concentrations, induces apoptotic cell death in Jurkat T cells in vitro. Z Onkol 1999, 31:14-20
9. Haux J, Solheim O, Isaksen T, Angelsen A: Digitoxin, in non-toxic concentrations, inhibits proliferation and induces cell death in prostate cancer cell lines. Z Onkol 2000, 32:11-16
10. Kawazoe N, Aiuchi T, Masuda Y, Nakajo S, Nakaya K: Induction of apoptosis by bufalin in human tumor cells is associated with a change of intracellular concentration of Na+ ions. J Biochem (Tokyo) 1999, 126:278-286
11. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA: Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000, 60:3807-3812
12. Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P: Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs 2001, 12:475-483
13. Friedman GD, Ury HK: Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980, 65:723-733
14. Friedman GD, Ury HK: Screening for possible drug carcinogenicity: second report of findings. J Natl Cancer Inst 1983, 71:1165-1175
15. Bernstein L, Ross RK: Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992, 52:5510-5515
16. Stenkvist B: Is digitalis a therapy for breast carcinoma? Oncol Rep 1999, 6:493-496
17. Lenfant-Pejovic MH, Mlika-Cabanne N, Bouchardy C, Auquier A: Risk factors for male breast cancer: a Franco-Swiss case-control study. Int J Cancer 1990, 45:661-665
18. McCarty MF: Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity. Med Hypotheses 1999, 53:459-85
19. Armstrong BK, Kricker A, English DR: Sun exposure and skin cancer. Australas J Dermatol 1997, 38:1-6
20. Cassell GH: Infectious causes of chronic inflammatory disease and cancer. Emerg Infect Dis 1998, 4:475-87
21. Kinlen LJ: High-contact paternal occupations, infection and childhood leukaemia: five studies of unusual population-mixing of adults. Br J Cancer 1997, 76:1539-45
22. Lever AF, Hole DJ, Gillis CR, McCallum IR, Mclnnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352:179-184
23. Schulman S, Lindmarker P: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. Engl J Med 2000, 342:1953-1958
24. Cohen HJ, Pieper CF, Hanlon JT, Wall WE, Burchett BM, Havlik RJ: Calcium channel blockers and cancer. Am J Med 2000, 108:210-215
25. Brestescher C, Pautier P, Farge D: [Chemotherapy and cardiotoxicity]. Ann Cardiol Angeiol 1995, 44:443-447
26. Britton M: Diagnostic errors discovered at autopsy. Acta Med Scand 1974, 196:203-210